ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "b3291f4c-f5e1-421b-a485-2ce0cf7fbecc"}, "_deposit": {"id": "25141", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "25141"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00025141", "sets": ["501"]}, "author_link": ["75038", "75039", "75040", "75041", "75042"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "e85", "bibliographicPageStart": "e75", "bibliographicVolumeNumber": "17", "bibliographic_titles": [{"bibliographic_title": "Clinical Lymphoma Myeloma and Leukemia", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment to both hematological malignancies and solid tumors appropriately. Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignant tumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignancies and determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649 patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomes between patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates for patients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from those for patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence of sMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval [CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients with sMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was a marginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.1016/j.clml.2017.09.006"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/27362"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.clml.2017.09.006", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2152-2650", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nishiwaki, Satoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuno, Shingo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Kotaro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurahashi, Shingo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugiura, Isamu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75042", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CLML_2017_435_Original_accepted_V1.pdf", "filesize": [{"value": "359.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 359000.0, "url": {"label": "CLML_2017_435_Original_accepted_V1.pdf ファイル公開日: 2018/12/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/25141/files/CLML_2017_435_Original_accepted_V1.pdf"}, "version_id": "0937d703-a1e4-46df-9616-41f02c90e7c6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Hematological malignancies", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Order of treatment", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Solid tumors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Synchronous multiple primary malignant tumors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Treatment discontinuation", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/27362", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2018-02-06"}, "publish_date": "2018-02-06", "publish_status": "0", "recid": "25141", "relation": {}, "relation_version_is_last": true, "title": ["Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies

http://hdl.handle.net/2237/27362
http://hdl.handle.net/2237/27362
c8805072-ea51-467b-9578-eab670243421
名前 / ファイル ライセンス アクション
CLML_2017_435_Original_accepted_V1.pdf CLML_2017_435_Original_accepted_V1.pdf ファイル公開日: 2018/12/01 (359.0 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2018-02-06
タイトル
タイトル Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
言語 en
著者 Nishiwaki, Satoshi

× Nishiwaki, Satoshi

WEKO 75038

en Nishiwaki, Satoshi

Search repository
Okuno, Shingo

× Okuno, Shingo

WEKO 75039

en Okuno, Shingo

Search repository
Suzuki, Kotaro

× Suzuki, Kotaro

WEKO 75040

en Suzuki, Kotaro

Search repository
Kurahashi, Shingo

× Kurahashi, Shingo

WEKO 75041

en Kurahashi, Shingo

Search repository
Sugiura, Isamu

× Sugiura, Isamu

WEKO 75042

en Sugiura, Isamu

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報 © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
キーワード
主題Scheme Other
主題 Hematological malignancies
キーワード
主題Scheme Other
主題 Order of treatment
キーワード
主題Scheme Other
主題 Solid tumors
キーワード
主題Scheme Other
主題 Synchronous multiple primary malignant tumors
キーワード
主題Scheme Other
主題 Treatment discontinuation
抄録
内容記述 The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment to both hematological malignancies and solid tumors appropriately. Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignant tumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignancies and determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649 patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomes between patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates for patients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from those for patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence of sMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval [CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients with sMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was a marginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Elsevier
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.1016/j.clml.2017.09.006
ISSN
収録物識別子タイプ PISSN
収録物識別子 2152-2650
書誌情報 en : Clinical Lymphoma Myeloma and Leukemia

巻 17, 号 12, p. e75-e85, 発行日 2017-12
著者版フラグ
値 author
URI
識別子 http://doi.org/10.1016/j.clml.2017.09.006
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/27362
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 13:44:44.312998
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3